Navigation Links
AtheroNova to Present at the 2013 Aegis Healthcare Conference in Las Vegas
Date:9/19/2013

ts are based upon the current beliefs and expectations of AtheroNova's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; AtheroNova's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of AtheroNova's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

AtheroNova undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in AtheroNova's 2012 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).


'/>"/>
SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. AtheroNova Announces a New Board Member
4. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
5. AtheroNova Releases 2011 Financial Results
6. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
7. AtheroNova Names New Director
8. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
9. AtheroNova Adds New Medical Advisor
10. Noted Atherosclerosis Researcher Joins AtheroNova Team
11. AtheroNova Announces Approval for Phase 1 by the Russian Ministry of Healthcare with Commencement of Human Trials Imminent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 The chemistry, taste, and health effects of ... article published by the nonprofit American Botanical Council (ABC). Recent ... and its effects on the phytochemical compounds in tea ( ... by Dr. Ahmed in the Yunnan ... implications for the future of medicinal botanicals. Dr. Ahmed,s ...
(Date:9/15/2014)... 15. September 2014 Die zweite jährliche ... vom 12. bis 18. Oktober stattfinden. Die IPAW ... Therapeutics Association (PPTA) und ihrer Mitgliedsunternehmen ... Das globale Bewusstsein für die Gewinnung von Quellplasma ... beim Retten und Verbessern von Leben zu würdigen ...
(Date:9/15/2014)... , 15 de septiembre de 2014 La segunda ... a cabo del 12 al 18 de octubre. Como iniciativa ... y de sus compañías miembro s, la IPAW se ... mundial en torno a la colección de fuentes de plasma ... plasma al salvar y mejorar las vidas , Aumento ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 Hydro ... ) announced today that it will be partnering ... CA ( http://www.proteaf.com ) for implementing its Shock ... value continuous processing. Continuous flow chemistry through ... chemical, pharmaceutical and petrochemical markets for decades. ...
Breaking Biology Technology:Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2
... Ohio -- In the quest for smaller, faster computer ... the exotic physics of the small. The problem: ... been equally exotic. That is, until now. ... to make quantum devices using technology common to the ...
... 15 Today, Formatech, Inc. announced that ... HIV/AIDS vaccine will be the first clinical candidate that is ... run is scheduled to be completed in January 2010. ... aseptically fill and finish one lot of the vaccine for ...
... 15 SIRO Clinpharm, a global Contract Research Organization (CRO) ... announced expansion of its Clinical Trials Supplies facility in Mumbai, ... pharmaceutical and biotech companies for storage and distribution of clinical ... , "We opened our clinical trials supplies warehouse ...
Cached Biology Technology:Quantum computer chips now 1 step closer to reality 2Quantum computer chips now 1 step closer to reality 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 2Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 4SIRO Clinpharm Strengthens its Clinical Trials Supplies Service Offering in India 2
(Date:9/15/2014)... Globally, cardiovascular disease (CVD) claims 17 million lives each ... additional 9.4 million. 1 New research presented by ... in Montpellier, France on September 15, 2014, suggests that ... , At the Milk and Dairy Products ... and risk for hypertension and CVD was examined by ...
(Date:9/15/2014)... the need for vitamin E and how much is ... levels of this essential micronutrient are especially critical for ... or may become pregnant. , A lifelong proper intake ... often complicated by the fact that this nutrient is ... alone. It has been estimated that only a tiny ...
(Date:9/12/2014)... DUBLIN, Ireland , September 12, 2014 ... and Markets ( http://www.researchandmarkets.com/research/trs4c7/global ) has announced ... Lock Industry Report 2014" report to ... Fingerprint Lock Industry Report 2014 is a ... state of the global fingerprint lock industry. ...
Breaking Biology News(10 mins):Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2Vitamin E intake critical during 'the first 1,000 days' 2Vitamin E intake critical during 'the first 1,000 days' 3Global Fingerprint Lock Industry Report 2014 2
... Spanish . Losses of managed honey bee ... 2009 to April 2010, according to a survey conducted by ... Service (ARS). Beekeepers identified starvation, poor weather, and weak colonies ... their operations. This is an increase from overall losses ...
... cognitive decline and for preventing Alzheimer,s diseasemental stimulation, ... studied over the years. However, an independent panel ... Health determined that the value of these strategies ... of decline or disease hasn,t been demonstrated in ...
... research team has taken a major step forward in understanding ... immune response by combining nanotechnology and cell biology. T cells ... response to infection. Christopher Cairo and his team ... cell response is switched on. Cairo looked at the molecule ...
Cached Biology News:Survey reports latest honey bee losses 2Panel finds insufficient evidence for Alzheimer's disease preventive measures 2Panel finds insufficient evidence for Alzheimer's disease preventive measures 3U Alberta-led team studies T cell activation with nanoparticles 2
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
in vitro Translation, Accessory Products...
Biology Products: